PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.3523
-0.0239 (-6.35%)
Nov 5, 2025, 4:00 PM EST - Market closed
PAVmed Revenue
PAVmed had revenue of $6.00K in the quarter ending June 30, 2025, a decrease of -99.39%. This brings the company's revenue in the last twelve months to $1.02M, down -73.36% year-over-year. In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth.
Revenue (ttm)
$1.02M
Revenue Growth
-73.36%
P/S Ratio
4.56
Revenue / Employee
$26,154
Employees
39
Market Cap
9.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00M | 543.00K | 22.15% |
| Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
| Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PAVM News
- 6 days ago - PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 - PRNewsWire
- 7 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 - PRNewsWire
- 21 days ago - Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit - PRNewsWire
- 4 weeks ago - PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement - PRNewsWire
- 7 weeks ago - Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs - PRNewsWire
- 7 weeks ago - Lucid Diagnostics Announces Closing of Public Offering of Common Stock - PRNewsWire
- 2 months ago - Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - PRNewsWire
- 2 months ago - Lucid Diagnostics Announces Proposed Public Offering of Common Stock - PRNewsWire